February 19, 2016 News by Margarida Azevedo, MSc ACTRIMS 2016 Talk Weighs Clinical Differences, Similarities in 2 Major Forms of MS Dr. Wayne Moore, from the University of British Columbia and the Vancouver General Hospital, will present an overview and analysis of the major histology and pathology aspects that characterize and differentiate relapsing-remitting multiple sclerosis (RRMS) and progressive forms of the disease, primary progressive MS (PPMS) and secondary progressive MS (SPMS).
February 19, 2016 News by Patricia Inacio, PhD Results of New SPMS Study to Be Presented at ACTRIMS At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18ā20 inĀ New Orleans, LA, researchers haveĀ gathered to discuss āProgressive MS: Bench to Bedside and Back,ā the meetingās theme. Secondary progressive multiple sclerosis (SPMS) is one of four types of MS, and is…
February 18, 2016 News by Margarida Azevedo, MSc Effects of Specific Antibodies on MS Neurodegeneration to Be Presented at ACTRIMS Forum Researchers from the University of Tennessee Health Science CenterĀ plan toĀ present the results of a study investigating the contribution of specific antibodies to the neurodegeneration and neuronal dysfunction observed in multiple sclerosis (MS). The studyās results are to be reported today, Feb. 18, at theĀ Americas Committee for Treatment and Research…
February 18, 2016 News by Patricia Silva, PhD Treadmill Exercise Benefits MS Patients, According to Study Presented at ACTRIMS Forum Brian M. Sandroff from the Kessler Foundation and Robert W. Mot with the University of Illinois will present the results of a study on the effects of exercise in patients with multiple sclerosis (MS) today, Feb.18, at the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS)…
February 18, 2016 News by Margarida Azevedo, MSc NIH Study into Progressive MS Biomarkers to Be Presented at ACTRIMS 2016 Scientists fromĀ the Neuroimmunological Diseases Unit at the National Institutes of Health (NIH) will present results ofĀ a study investigating several biomarkers that might leadĀ to a more sensitive and accurate diagnostic test of central nervous system (CNS) inflammation, aĀ keyĀ aspect ofĀ progressive multiple sclerosis (MS). The data is being reportedĀ today, Feb.18, at the…
February 18, 2016 News by Patricia Silva, PhD ACTRIMS Session on MS Progression to Emphasize Continuing Treatment of Advancing Disease The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 starts today, Feb. 18, in New Orleans, Louisiana, and runs through Saturday, Feb. 20. The opening day’sĀ Session 1, titled “Emerging Concepts in MS,” placesĀ special focus onĀ cutting-edge studies onĀ the pathogenic mechanisms in multiple sclerosis (MS), new measures of…
February 18, 2016 News by Margarida Azevedo, MSc Anavex Life Sciences to Present Preclinical Data on Lead MS Drug Candidate at ACTRIMS 2016 Anavex Life Sciences, a biopharmaceutical company focused on the development of new therapies for neurodegenerative and central nervous system (CNS) diseases, among others, recently announced the presentation of preclinical data forĀ one of its lead drug candidates, ANAVEX2-73, as a multiple sclerosis (MS) treatment. The preclinical studyās lead investigator, Dr.
February 18, 2016 News by BioNews Staff FDA Grants ‘Breakthrough Therapy’ Designation to Genentechās Ocrelizumab for PPMS Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment forĀ primary progressive multiple sclerosis (PPMS),Ā Breakthrough Therapy DesignationĀ based on positiveĀ Phase 3 clinical trial results showing thatĀ ocrelizumab significantly reduced disability progression and other disease activity markers compared toĀ placebo. The FDA designation is…
February 16, 2016 News by Charles Moore MS Treatment and Research Forum, ACTRIMS, Kicks Off Thursday in New Orleans The first standalone forum held by the Madison, Wisconsin-based Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) gets underwayĀ Ā Thursday, Feb. 18, and runs through Feb. 20 in New Orleans, Louisiana. The forum, “Progressive MS: From Bench to Bedside and Back,” is at the Hyatt Regency New Orleans at…
January 22, 2016 News by Patricia Silva, PhD EMD Serono Gains Exclusive US Rights to MS Drug for Relapsing Forms of Disease EMD Serono, theĀ North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over RebifĀ (interferon beta-1a) inĀ the United States. RebifĀ Ā is a treatment for relapsing forms of multiple sclerosis (MS). Rebif, an approved drug, is usedĀ to decrease the frequency of MS relapses and delay the occurrence of…
December 14, 2015 News by Patricia Silva, PhD 2016 Multiple Sclerosis Forum to Focus on Distinctions in Disease Forms Dr. Jerry S. WolinskyĀ ofĀ the University of Texas in Houston, will giveĀ the first Kenneth P. Johnson Memorial Lecture at the opening day of the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 in New Orleans, focusing on distinctions between relapsing and progressive disease forms. ACTRIMS…
September 11, 2014 News by Patricia Silva, PhD Receptos to Present Data on RMS Treatment Trial at MSBoston 2014 Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…
August 14, 2014 News by Patricia Silva, PhD Big Multiple Sclerosis Conference Scheduled For September in Boston Just yesterday, the President of theĀ Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS),Ā Suhayl Dhib-Jalbut, publicly announced the details of this year’sĀ MSBoston2014Ā conference, in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). According to Dhib-Jalbut — who is also the…